At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
LX4211 Low Dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX4211 in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating LX4211 Low Dose, LX4211 High Dose, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedAug 2009
Primary CompletionDec 2009
TodayJul 2026
First PostedAug 19, 2009
Enrollment StartAug 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.9 years ago
Interventions
LX4211 Low Dosedrug
A low dose of LX4211; daily oral intake for 28 days
LX4211 High Dosedrug
A high dose of LX4211; daily oral intake for 28 days
Placebodrug
Matching placebo dosing with daily oral intake for 28 days